Fig. 4: Cross-neutralizing activity in sera from individuals infected with WT, B.1.1.7, B.1.351 or B.1.617.2 SARS-CoV-2 variants.
a, Schematic showing the position of spike mutations in the B.1.1.7, B.1.351 and B.1.617.2 variants. The major spike domains are indicated. b–e, Cross-neutralizing activity of sera from individuals infected in wave 1 (b; n = 20), with B.1.1.7 (c; n = 20), with B.1.351 (d; n = 5) or with B.1.617.2 (e; n = 20) against SARS-CoV-2 VOCs. Sera were collected in the acute phase of infection (wave 1 at 12–53 days POS, B.1.1.7 at 11–33 days POS, B.1.351 at 26–52 days POS, and B.1.617.2 at 12–32 days POS) and matched between groups. The dotted line represents the cut-off for the assay. The asterisk shows homologous neutralization. Each dot represents one individual, and matched data points for neutralization of different spike variants by the same serum sample are connected by lines. The red line represents the GMT against that virus, which is also reported as numerical values at the top of each graph. f, The fold reduction in GMT of sera from individuals infected with the different variants against WT, B.1.1.7, B.1.351 and B.1.617.2.
